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Abstract
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recur-
rent episodes of mania and depression. BD shows substantial clinical and genetic overlap
with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying
this etiological overlap remain largely unknown. A recent SCZ genome wide association
study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent
genome-wide significant single nucleotide polymorphisms (SNPs). The present study inves-
tigated whether these SCZ-associated SNPs also contribute to BD development through
the performance of association testing in a large BD GWAS dataset (9747 patients, 14278
controls). After re-imputation and correction for sample overlap, 22 of 107 investigated SCZ
SNPs showed nominal association with BD. The number of shared SCZ-BD SNPs was sig-
nificantly higher than expected (p = 1.46x10-8). This provides further evidence that SCZ-
associated loci contribute to the development of BD. Two SNPs remained significant after
Bonferroni correction. The most strongly associated SNP was located near TRANK1, which
is a reported genome-wide significant risk gene for BD. Pathway analyses for all shared
SCZ-BD SNPs revealed 25 nominally enriched gene-sets, which showed partial overlap in
terms of the underlying genes. The enriched gene-sets included calcium- and glutamate sig-
naling, neuropathic pain signaling in dorsal horn neurons, and calmodulin binding. The pres-
ent data provide further insights into shared risk loci and disease-associated pathways for
BD and SCZ. This may suggest new research directions for the treatment and prevention of
these two major psychiatric disorders.
Introduction
Bipolar disorder (BD) is a severe neuropsychiatric disease characterized by recurrent episodes
of mania and depression. BD has an estimated lifetime prevalence of around 1% [1], and a her-
itability of around 70% [2]. BD shows substantial clinical and genetic overlap with other
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psychiatric disorders [3, 4]. An analysis of the genome-wide genotype data of the Psychiatric
Genomics Consortium (PGC) revealed a 68% genetic correlation between BD and schizophre-
nia (SCZ), which was the highest correlation with BD of all psychiatric diseases investigated
[3]. However, the genes involved in this etiological overlap remain largely unknown.
Although research into BD and SCZ has identified a number of susceptibility genes, the
respective biological pathways still await identification. For BD, recent genome wide associa-
tion studies (GWAS) have identified a number of risk loci [5–13].
For SCZ, a PGC meta-analysis of data from >36,000 patients and 113,000 controls identi-
fied 128 independent genome-wide significant single nucleotide polymorphisms (SNPs) in
108 genetic loci [14].
The aim of the present study was to investigate whether these 128 SCZ-associated SNPs also
contribute to the development of BD. For this purpose, we performed association testing of
these SNPs in our large BD GWAS dataset [12]. In addition, we analyzed whether the genome-
wide significant BD-associated SNPs identified in our BD GWAS [12] show association with
SCZ.
Materials and methods
Sample description
The analyses were performed using data from our previous GWAS of BD (9,747 patients and
14,278 controls) [12]. This GWAS dataset combined: (i) the MooDS data (collected from Can-
ada, Australia, and four European countries); and (ii) the GWAS results for BD of the large
multinational PGC [5]. The patients were assigned the following diagnoses (DSM-IV,
DSM-IIR, Research Diagnostic Criteria): BD type 1 (n = 8,001; 82.1%); BD type 2 (n = 1,212;
12.4%); schizoaffective disorder (bipolar type; n = 269; 2.8%); and BD not otherwise specified
(n = 265, 2.7%) [12]. The study was approved by the local ethics committees of the participat-
ing centers (University Hospital Wu¨rzburg, Germany; Central Institute of Mental Health,
Mannheim, Germany; University of Essen, Germany; Ludwig Maximilians University,
Munich, Germany; Prince of Wales Hospital, Sydney, Australia; Queensland Institute of Medi-
cal Research, Brisbane, Australia; Poznan University of Medical Sciences, Poland; University
of Szczecin, Poland; speciality mood disorders clinics in Halifax and Ottawa, Canada; Russian
State Medical University, Moscow, Russian Federation; Kursk State Medical University, Rus-
sian Federation; Regional University Hospital of Malaga, Spain; and Instituto Municipal de
Asistencia Sanitaria, IMAS-IMIM, Barcelona, Spain) [12]. Written informed consent was
obtained from all participants prior to inclusion [12].
Genome-wide significant loci for SCZ and BD
For the 128 linkage disequilibrium (LD)-independent genome-wide significant SNPs for SCZ,
genetic information was obtained from the supplementary information of the SCZ GWAS of
the PGC [14]. This is the largest GWAS of SCZ to date.
Genome-wide significant SNPs for BD were obtained from our BD GWAS [12].
Imputation and meta-analysis
Different reference panels were used for the imputation of the MooDS and PGC BD genotype
data (1,000 Genomes Project, February 2012 release; and HapMap phase 2 CEU, respectively).
Therefore, the summary statistics of the PGC BD GWAS [5] were imputed using the 1,000
Genomes Project reference panel and ImpG-Summary. The latter is a recently proposed
method for the rapid and accurate imputation of summary statistics [15]. This resulted in
Shared bipolar disorder and schizophrenia risk loci
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z-scores for>20 million SNPs. A total of 111 SCZ-associated SNPs could be mapped to the re-
imputed PGC BD GWAS data. The remaining variants were either located on the X-chromo-
some (n = 3), or represented insertions or deletions (n = 14) which could not be imputed by
the applied method. In total, 107 of the 111 SCZ-associated SNPs could be identified in the
MooDS BD GWAS.
A meta-analysis for these 107 SNPs was then performed by combining the PGC BD GWAS
and the MooDS BD GWAS, and using the sample size based strategy implemented in METAL
[16].
Analysis of shared BD-SCZ SNPs
The risk alleles for all nominally significant SNPs in our BD GWAS [12] were compared to
those reported in the PGC SCZ GWAS.
The SCZ discovery meta-analysis comprised data from 35,476 patients and 46,839 controls.
Our BD GWAS comprised data from 9,747 patients and 14,278 controls [12]. To correct for an
overlap between the two studies of around 500 patients and 9,200 controls [17, 18], we applied
the framework of a bivariate normal distribution for the z-scores from both studies, corre-
sponding to a specific SNP. Since the significant hits from a study were selected from different
chromosomal regions, we assumed that the z-scores within a study are independent. Accord-
ing to the LD Score regression method [19], the mean inflation of the test statistics provides an
approximation of the variance of the z-scores. By considering the set of SNPs in the HapMap3
reference panel [20], the calculated variance was approximately 1.82 for SCZ and 1.24 for BD.
From equation (16) in Bulik-Sullivan et al. [19] (Supplementary Material), the covariance
between z-scores was calculated to be 0.1644, under the assumption of no genetic correlation.
This yielded a correlation of approximately 0.109. To confirm the validity of these theoretical
calculations, we estimated the covariance of z-scores due to sample overlap by applying the LD
Score regression software directly to the results of the PGC SCZ GWAS and our BD GWAS.
After restriction to the well-imputed SNPs of HapMap3, the software estimated a covariance
of 0.1707. This result provides further evidence that the degree of sample overlap was correctly
estimated in the present study.
The z-scores for the 107 SCZ-associated SNPs were extracted from the PGC SCZ discovery
study. The corresponding z-scores were extracted from our BD GWAS [12]. Using the values
above, the mean and the variance of the normal distribution for the BD z-scores were deter-
mined, given the z-scores from the PGC SCZ discovery study. After the transformation of the
initial z-scores from our BD GWAS, a total of 22 of 107 z-scores for BD had corresponding
two-sided association p-values of<5% (Table 1).
Analogously, the z-scores for the genome-wide significant BD SNPs were extracted from
our BD GWAS [12], and the corresponding z-scores were extracted from the PGC SCZ discov-
ery study. Of the five BD-associated lead SNPs in our BD GWAS, one SNP (rs6550435) was in
high LD (r2 = 0.897, SNAP [21]) with a genome-wide SCZ-associated SNP (rs75968099), and
was thus excluded from this additional analysis. For the remaining four SNPs, the transforma-
tion was computed in the other direction. After correction for sample overlap, no BD SNP
showed association with SCZ.
Bonferroni correction for multiple testing was performed by multiplying the nominal p-val-
ues with the number of investigated SNPs (n = 107+4 = 111).
Pathway analysis
Pathway analysis for all 22 shared SCZ-BD SNPs was performed using Ingenuity Pathway
Analysis (IPA; http://www.ingenuity.com/) [22, 23] and INRICH [24].
Shared bipolar disorder and schizophrenia risk loci
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In IPA, each gene is represented in a global molecular network, which is designed using
information from the Ingenuity Pathway Knowledge Base. ‘Networks’ were generated algorith-
mically, and on the basis of their connectivity in terms of activation, expression, and transcrip-
tion. Molecular relationships between genes are represented by connecting lines between
nodes, as supported by published data stored in the Ingenuity Pathway Knowledge Base and/
or PubMed. For the purposes of the present study, the canonical pathway analysis available in
IPA was applied. Here, an SNP is mapped to a gene if it falls within the gene-coding region or
within the 2 kilobase (kb) upstream/ 0.5 kb downstream range of the gene-coding region. This
resulted in the inclusion of 13 genes in the pathway analysis. Significant pathways were filtered
in order to achieve a minimum of two genes per set. The significance of the association
between the SNP-associated genes mapped by IPA and the canonical pathway was measured
using Fisher’s exact test.
INRICH [24] was used as a secondary pathway analysis tool, as it enables examination of
enriched association signals of LD-independent genomic intervals. Gene Ontology (GO) gene
sets were extracted from the Molecular Signatures Database (MSigDB), version 5.0 (Broad
Institute, http://software.broadinstitute.org/gsea/msigdb/index.jsp, downloaded in September
2015). The size of the extracted gene sets ranged from 10 to 200 genes, resulting in 1,268 target
sets for testing. The intervals around the 22 SNPs of interest were based on empirical estimates
of LD from PLINK (http://pngu.mgh.harvard.edu/purcell/plink/). SNPs were assigned to
Table 1. Schizophrenia-associated SNPs with a p-value of <0.05 in our bipolar disorder GWAS data after correction for sample overlap.
SNP Chr Position Alleles P BD Meta Pcorr BD Meta P PGC SCZ Nearby Gene/s
rs75968099 3 36858583 T/C 2.03 x 10−5 0.0022 1.05 x 10−13 TRANK1
rs2535627 3 52845105 T/C 4.68 x 10−5 0.0052 4.26 x 10−11 ITIH3-ITIH4
rs6704641 2 200164252 A/G 0.0030 0.3331 8.33 x 10−9 SATB2
rs140505938 1 150031490 T/C 0.0032 0.3597 4.49 x 10−10 VPS45
rs7893279 10 18745105 T/G 0.0043 0.4770 1.97 x 10−12 CACNB2
rs6704768 2 233592501 A/G 0.0063 0.6991 2.32 x 10−12 GIGYF2
rs12704290 7 86427626 A/G 0.0075 0.8315 3.33 x 10−10 GRM3
rs211829 7 110048893 T/C 0.0088 0.9778 3.71 x 10−8 -
rs3735025 7 137074844 T/C 0.0098 >0.9999 3.28 x 10−9 DGKI
rs324017 12 57487814 A/C 0.0098 >0.9999 2.13 x 10−8 NAB2
rs2909457 2 162845855 A/G 0.0109 >0.9999 4.62 x 10−8 SLC4A10-DPP4
rs9922678 16 9946319 A/G 0.0120 >0.9999 1.28 x 10−8 GRIN2A
rs950169 15 84706461 T/C 0.0181 >0.9999 1.62 x 10−11 ADAMTSL3
rs55661361 11 124613957 A/G 0.0301 >0.9999 2.8 x 10−12 NRGN
rs10043984 5 137712121 T/C 0.0307 >0.9999 1.09 x 10−8 KDM3B
rs1498232 1 30433951 T/C 0.0323 >0.9999 2.86 x 10−9 LOC101929406
rs6434928 2 198304577 A/G 0.0351 >0.9999 2.06 x 10−11 SF3B1-COQ10B
rs2007044 12 2344960 A/G 0.0367 >0.9999 3.22 x 10−18 CACNA1C
rs8044995 16 68189340 A/G 0.0380 >0.9999 1.51 x 10−8 NFATC3
rs56205728 15 40567237 A/G 0.0387 >0.9999 4.18 x 10−9 PAK6
rs2693698 14 99719219 A/G 0.0429 >0.9999 4.8 x 10−9 BCL11B
rs832187 3 63833050 T/C 0.0465 >0.9999 1.43 x 10−8 THOC7
Single nucleotide polymorphisms (SNPs) are shown according to their p-values in our bipolar disorder (BD) GWAS [12] following correction for sample
overlap. Chromosomal positions refer to genome build GRCh37 (hg19). Abbreviations: Chr, chromosome; P BD Meta, p-value in our BD GWAS [12] after
correction for sample overlap; Pcorr BD Meta, p-value in our BD GWAS [12] after correction for sample overlap and Bonferroni correction for multiple testing;
P PGC SCZ, p-value in the PGC schizophrenia GWAS [14].
doi:10.1371/journal.pone.0171595.t001
Shared bipolar disorder and schizophrenia risk loci
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genes using 50 kb up- and downstream windows. In total, 21 intervals were tested for the 1,268
target sets.
In IPA, correction for multiple testing was performed using the Benjamini Hochberg
method. In INRICH, the empirical gene set p-value was corrected for multiple testing using
bootstrapping-based re-sampling.
Results
A total of 107 of the 128 SCZ-associated SNPs could be mapped to both the re-imputed PGC
BD GWAS and the MooDS BD GWAS data. A meta-analysis of these 107 SNPs was then per-
formed using METAL [16].
After correction for sample overlap, 22 of the 107 SCZ-associated SNPs showed nominally
significant p-values in our BD GWAS (Table 1, S1 Table). For all 22 SNPs, the direction of the
effect was identical to that observed in the PGC SCZ GWAS [14]. Of the five genome-wide sig-
nificant BD-associated SNPs identified in our BD GWAS, one SNP (rs6550435) was in high
LD (r2 = 0.897) with a genome-wide SCZ-associated SNP (rs75968099). None of the remaining
four genome-wide significant BD-associated SNPs showed a nominally significant association
with SCZ after correction for sample overlap (data not shown).
The number of SCZ SNPs with a p-value of<0.05 in our BD GWAS (n = 22) was signifi-
cantly higher than expected (p = 1.46x10-8, binomial test). This provides further evidence that
SCZ-associated loci contribute to the development of BD.
The most strongly associated SNP was located near the gene TRANK1 (Table 1, p = 2.03x10-
5), which is a reported genome-wide significant risk gene for BD [7, 12]. The other nominally
associated SCZ-BD SNPs implicated loci which contain interesting candidate genes for BD
and SCZ. These include the chromatin remodeling gene SATB2, the glutamate receptor genes
GRM3 and GRIN2A, and the calcium channel subunit gene CACNB2. The latter is a reported
genome-wide significant risk gene for a number of psychiatric disorders, including BD and
SCZ [17].
After Bonferroni correction for multiple testing, two SNPs (rs75968099, rs2535627) showed
significant association with BD (pcorr = 2.25x10-3 and pcorr = 5.19x10-3, respectively).
Pathway analysis using IPA revealed nine pathways with nominally significant enrichment
(Fig 1). Of these, eight remained significantly enriched after Benjamini Hochberg correction
for multiple testing. The pathway with the strongest enrichment was synaptic long term poten-
tiation (pcorr = 0.003, Fig 2, S2 Table). In addition, significant enrichment was found for gluta-
mate receptor- and calcium signaling; neuropathic pain signaling in dorsal horn neurons; and
CREB signaling in neurons.
These findings are consistent with previous pathway analyses of BD and SCZ [5, 25–27].
The present analysis also confirmed the glutamatergic signaling pathway, which was consid-
ered provisional in a recent review [28].
Pathway analysis using INRICH identified a total of 16 nominally significant gene-sets,
which showed partial overlap in terms of the underlying genes. The enriched gene-sets include
voltage-gated calcium channel complex/activity; calmodulin binding; glutamate receptor activ-
ity; and M phase of the mitotic cell cycle (Fig 3). None of these gene-sets remained significantly
enriched for associations after correction for multiple testing (Fig 3, S3 Table).
Discussion
The present analyses revealed a significant enrichment of BD-associated SNPs within known
SCZ-associated loci (p = 1.46x10-8). This is consistent with previous reports of overlapping
genetic susceptibility for BD and SCZ [4, 29, 30].
Shared bipolar disorder and schizophrenia risk loci
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The most strongly associated SNP was located near TRANK1, which is a reported genome-
wide significant risk gene for BD [7]. The second SNP with significant BD association after
correction for multiple testing (rs2535627, Table 1) was located in a genomic region on chro-
mosome 3. This region contains multiple genes, including inter-alpha-trypsin inhibitor heavy
chain 3 (ITIH3) and -4 (ITIH4). Common variation at the ITIH3-ITIH4 region has been iden-
tified as a genome-wide significant risk factor for five different psychiatric disorders, including
SCZ and BD [17].
Interestingly, the GWAS index SNP rs2535627 represents a Bonferroni-significant fetal
brain methylation quantitative trait locus (mQTL), as it has been associated with DNA methyl-
ation at cg11645453. The latter is located in the 5’ untranslated region of ITIH4 [31]. This sug-
gests that the SCZ-BD associated SNP rs2535627 might contribute to disease susceptibility by
altering the expression of ITIH4 in the brain [32]. This hypothesis is supported by a recent
study, which found that the G-allele of the SNP rs4687657—which is in moderate LD with
rs2535627 (r2 = 0.426, D’ = 1.000, SNAP [21])—was significantly associated with reduced
ITIH4 expression in the postmortem dorsolateral prefrontal cortex of controls [33].
SNPs with nominal association implicated several other plausible susceptibility genes for
BD and SCZ (Table 1). These include SATB2, which is a highly conserved chromatin remodel-
ing gene [34]. A previous animal study demonstrated that SATB2 was an essential regulator of
axonal connectivity in the developing neocortex [35]. In addition, mutations spanning SATB2
have been reported in patients with neurodevelopmental disorders, including autism [36, 37].
The present SCZ-BD associated SNPs implicated three promising candidate genes for
shared BD-SCZ etiology, i.e., CACNB2, GRM3, and GRIN2A. The gene CACNB2 encodes an
Fig 1. Results of the Ingenuity Pathway Analysis. Results of the Ingenuity Pathway Analysis (IPA) are shown in bar plot format. The x-axis shows
negative logarithmic enrichment p-values for all associated pathways containing two and more genes prior to- (gray) and after- (blue) Benjamini
Hochberg correction for multiple testing. The red horizontal line indicates a p-value of 0.05.
doi:10.1371/journal.pone.0171595.g001
Shared bipolar disorder and schizophrenia risk loci
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Fig 2. IPA pathway synaptic long term potentiation. Results of the Ingenuity pathway analysis (IPA) for the pathway
“Synaptic Long Term Potentiation” are shown. Shared schizophrenia-bipolar disorder associated genes (GRIN2A, GRM3,
CACNA1C) are highlighted in purple.
doi:10.1371/journal.pone.0171595.g002
Shared bipolar disorder and schizophrenia risk loci
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L-type voltage-gated calcium channel subunit, and is a reported genome-wide significant risk
gene for several psychiatric disorders, including SCZ and BD [17].
The gene GRM3 encodes a metabotropic glutamate receptor. GRM3 is expressed predomi-
nantly in astrocytes, and has been investigated by previous authors as a potential therapeutic
target in SCZ [14]. A further SCZ-BD SNP was located near GRIN2A, which encodes an
NMDA receptor subunit involved in glutamatergic neurotransmission and synaptic plasticity
[14]. Interestingly, rare mutations in GRIN2A have been reported in patients with SCZ [38].
The present pathway analysis implicated calcium- and glutamate signaling, and neuro-
pathic pain signaling in dorsal horn neurons. These findings are consistent with previous path-
way analyses of BD and SCZ [5, 25–27]. These results thus provide further evidence that
neurotransmitter signaling and synaptic processes are involved in the development of BD and
SCZ.
Fig 3. Results of the INRICH pathway analysis. Results of the INRICH pathway analysis are shown in bar plot format. The x-axis shows negative
logarithmic enrichment p-values for all nominally associated pathways containing two and more genes prior to- (gray) and after- (blue) correction for
multiple testing. The red horizontal line indicates a p-value of 0.05.
doi:10.1371/journal.pone.0171595.g003
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Our enrichment analysis identified a total of 25 enriched gene-sets, which showed partial
overlap in terms of the underlying genes. One of the major characteristics of the GO database
is its hierarchical structure. This structure involves the use of broad ‘parent’ terms, which can
be divided into more distinctive ‘child’ terms [39]. After taking these relations into account,
we categorized our findings from the GO database into five different parent gene-set families:
channel activity, lipase activity, mitotic cell cycle, calmodulin binding, and glutamate receptor
signaling (S3 Table).
The results generated by IPA and INRICH were broadly consistent, despite the fact that the
underlying databases were different. In some cases, pathways were implicated by the same
genes, e.g., glutamate signaling was implicated by GRIN2A and GRM3 in both IPA and
INRICH. In other cases, pathways were implicated by differing genes, e.g., calcium channel
activity/calcium signaling was implicated by NFATC3 and GRIN2A in IPA, and by CACNB2
and CACNA1C in INRICH (S2 and S3 Tables). This provides further support for the involve-
ment of these pathways in the development of BD and SCZ.
The most strongly enriched pathway according to IPA was synaptic long term potentiation
(Fig 2). This pathway has been implicated in learning and memory mechanisms [40]. Interest-
ingly, several previous studies have provided evidence for the involvement of impaired long
term potentiation in the pathophysiology of SCZ [41, 42]. In the present study, this pathway
result was driven by the genes GRIN2A,GRM3, and CACNA1C. The products of all three
genes are located in the postsynaptic membrane (Fig 2), which may suggest that dysfunction at
the postsynaptic level is an early step in the development of BD and SCZ [43].
The identified pathways support specific hypotheses regarding the shared neurobiology of
BD and SCZ. Notably, our results provide further evidence that glutamate signaling might be
involved in the development of both SCZ and BD [44]. This would be consistent with the
observation from routine clinical practice that SCZ drugs which target glutamate signaling are
also effective in BD patients with psychosis or mania [44].
A limitation of the present study was the substantial sample overlap between our BD
GWAS [12] and the SCZ GWAS of the PGC [14], since this creates an inflation of effect. To
address this, the correlation of z-scores between the two studies was calculated. Based on this
information, the initial z-scores were then transformed to correct for sample overlap. To esti-
mate the correlation of test statistics, the publically available summary statistics of the PGC
SCZ GWAS were used, which comprise the results of the discovery phase (35,476 patients,
46,839 controls). As the effect of shared samples might be stronger in the discovery sample
than in the complete meta-analysis, we may have overestimated the correlation of test statistics
between the two GWAS. Therefore our correction for sample overlap may have been too con-
servative. However, since the inflation effect introduced by shared samples might be different
for independent SNPs compared to the average correlation of test statistics, we assume that
our conservative approach was appropriate in terms of reducing false positive results. In future
cross-disorder studies, shared samples should be identified and removed from one study on
the basis of individual genotype data. This was not possible in the present study, as the analyses
were based on summary statistics.
The present data provide further insights into shared risk loci and disease-associated path-
ways for BD and SCZ.
However, further research is required to determine precisely how the genetic risk variants
correlate with particular diagnoses or clinical symptoms. For example, in a previous study, we
showed that common variation at the NCAN locus was associated with both BD [8] and SCZ
[45]. Genetic variation at the NCAN locus thus represents a cross-diagnosis contributory fac-
tor, which may relate to a specific mania symptom-complex [46]. Therefore, future studies are
warranted to determine the specific BD and SCZ phenotypic dimensions to which the present
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variants contribute. Such findings may suggest new research directions for the treatment and
prevention of BD and SCZ.
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S1 Table. Overview of the 107 investigated schizophrenia-associated SNPs and respective
test statistics. Single nucleotide polymorphisms (SNPs) are shown according to their p-values
in our bipolar disorder (BD) GWAS [12] following correction for sample overlap. Chromo-
somal positions refer to genome build GRCh37 (hg19). An imputation accuracy metric of 1
indicates that the respective SNP was not imputed using ImpG-Summary. Abbreviations: Chr,
chromosome; A1, the allele to which the z-score is predicted; A2, other allele; Z/P BD Meta, z-
score/p-value in our BD GWAS [12] after correction for sample overlap; Pcorr BD Meta, p-
value in our BD GWAS [12] after correction for sample overlap and Bonferroni correction for
multiple testing; Z/P PGC SCZ (discovery), derived z-score/p-value in the PGC schizophrenia
GWAS (discovery phase) [14].
(XLSX)
S2 Table. Results of the Ingenuity Pathway Analysis. Enrichment p-values for all nine nomi-
nally associated pathways containing two and more genes are shown both prior to and after
Benjamini Hochberg (B-H) correction for multiple testing. Abbreviation: No. Genes in Path-
way, total number of genes in each pathway.
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S3 Table. Results of the INRICH pathway analysis. Empirical gene set p-values for all 16
nominally associated pathways containing two and more genes are shown. The p-values were
corrected for multiple testing using bootstrapping-based re-sampling (corrected p-value).
Abbreviations: GO, Gene Ontology; No. Genes in Pathway, total number of genes in each
pathway.
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